A gene expression signature of invasive potential in metastatic melanoma cells

PLoS ONE

Volumn 4, Issue 12, 2009, Pages

  Jeffs, Aaron R ^a   Glover, Amy C ^b   Slobbe, Lynn J ^a   Wang, Li ^c   He, Shujie ^a   Hazlett, Jody A ^a   Awasthi, Anshul ^d   Woolley, Adele G ^a   Marshall, Elaine S ^e   Joseph, Wayne R ^e   Print, Cristin G ^c   Baguley, Bruce C ^e   Eccles, Michael R ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF YORK   (United Kingdom)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d UNIVERSITY OF OTAGO   (New Zealand)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN; PROTEIN EDNRB; PROTEIN PLAUR; PROTEIN TYR; PROTEIN VCAN; SCLEROPROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER INVASION; CELL INVASION; GENE EXPRESSION; HUMAN; HUMAN CELL; MELANOMA CELL; METASTASIS; NUCLEOTIDE SEQUENCE;

CELL LINE, TUMOR; CELL MOVEMENT; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; GENOME, HUMAN; HUMANS; MELANOMA; MODELS, GENETIC; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; SKIN NEOPLASMS;

EID: 77954049394     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008461     Document Type: Article

References (50)

1. Bishop JN, Bataille V, Gavin A, Lens M, Marsden J, et al. (2007) The prevention, diagnosis, referral and management of melanoma of the skin: concise guidelines. Clin Med 7: 283-290.
2. Hocker TL, Singh MK, Tsao H (2008) Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J Invest Dermatol 128: 2575-2595.
3. Francken AB, Accortt NA, Shaw HM, Wiener M, Soong SJ, et al. (2008) Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol 15: 1476-1484.
4. Jacobs LK, Lange JR, Balch CM (2008) Sorting through the heterogeneity of recurrent melanoma. Ann Surg Oncol 15: 1280-1281.
5. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, et al. (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19: 3622-3634.
6. New Zealand Health Information Service (2007) Cancer: New Registrations and Deaths 2004, Wellington, Ministry of Health, New Zealand Government ISBN 978-0-478-30785-6.
7. Richardson A, Fletcher L, Sneyd M, Cox B, Reeder AI (2008) The incidence and thickness of cutaneous malignant melanoma in New Zealand 1994-2004. N ZMed J 121:18-26.
8. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511.
9. Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, et al. (2001) Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344: 1196-1206.
10. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
11. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, et al. (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362: 362-369.
12. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. (2002) A gene- expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
13. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, et al. (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406: 536-540.
14. Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, et al. (2005) The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A 102: 6092-6097.
15. Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, et al. (2006) Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 19: 290-302.
16. Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, et al. (2008) The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 1: 13.
17. Ren S, Liu S, Howell P, Jr., Xi Y, Enkemann SA, et al. (2008) The impact of genomics in understanding human melanoma progression and metastasis. Cancer Control 15: 202-215.
18. Hoek KS, Schlegel NC, Eichhoff OM, Widmer DS, Praetorius C, et al. (2008) Novel MITF targets identified using a two-step DNA microarray strategy. Pigment Cell Melanoma Res 21: 665-676.
19. Hoek KS, Eichhoff OM, Schlegel NC, Dobbeling U, Kobert N, et al. (2008) In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res 68: 650-656.
20. Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T, et al. (2008) Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS ONE 3: e2734.
21. Petermann KB, Rozenberg GI, Zedek D, Groben P, McKinnon K, et al. (2007) CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Invest 117: 3922-3929.
22. Goodall J, Carreira S, Denat L, Kobi D, Davidson I, et al. (2008) Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative mel- anoma cells. Cancer Res 68: 7788-7794.
23. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436: 117-122.
24. Nunez NP, Liu H, Meadows GG (2006) PPAR-gamma ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells. Cancer Lett 236: 133-141.
25. Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, et al. (2005) Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 11: 7234-7242.
26. Folberg R, Arbieva Z, Moses J, Hayee A, Sandal T, et al. (2006) Tumor cell plasticity in uveal melanoma: microenvironment directed dampening of the invasive and metastatic genotype and phenotype accompanies the generation of vasculogenic mimicry patterns. Am J Pathol 169: 1376-1389.
27. Carreira S, Goodall J, Denat L, Rodriguez M, Nuciforo P, et al. (2006) Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev 20: 3426-3439.
28. Lekmine F, Chang CK, Sethakorn N, Das Gupta TK, Salti GI (2007) Role of microphthalmia transcription factor (Mitf) in melanoma differentiation. Biochem Biophys Res Commun 354: 830-835.
29. Busca R, Berra E, Gaggioli C, Khaled M, Bille K, et al. (2005) Hypoxia- inducible factor 1{alpha} is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J Cell Biol 170: 49-59.
30. Garrett SC, Varney KM, Weber DJ, Bresnick AR (2006) S100A4, a mediator of metastasis. J Biol Chem 281: 677-680.
31. Bjornland K, Winberg JO, Odegaard OT, Hovig E, Loennechen T, et al. (1999) S100A4 involvement in metastasis: deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme. Cancer Res 59: 4702-4708.
32. Trudel D, Fradet Y, Meyer F, Harel F, Tetu B (2008) Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry. Hum Pathol 39: 731-739.
33. Mendes O, Kim HT, Lungu G, Stoica G (2007) MMP2 role in breast cancer brain metastasis development and its regulation by TIMP2 and ERK1/2. Clin Exp Metastasis 24: 341-351.
34. Wong FH, Huang CY, Su LJ, Wu YC, Lin YS, et al. (2009) Combination of microarray profiling and protein-protein interaction databases delineates the minimal discriminators as a metastasis network for esophageal squamous cell carcinoma. Int J Oncol 34: 117-128.
35. Ivanov SV, Ivanova AV, Salnikow K, Timofeeva O, Subramaniam M, et al. (2008) Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors. Biochem Biophys Res Commun 370: 536-540.
36. Ma C, Rong Y, Radiloff DR, Datto MB, Centeno B, et al. (2008) Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev 22: 308-321.
37. Domenzain-Reyna C, Hernandez D, Miquel-Serra L, Docampo MJ, Badenas C, et al. (2009) Structure and regulation of the versican promoter: The versican promoter is regulated by AP-1 and TCF transcription factors in invasive human melanoma cells. J Biol Chem.
38. Bedogni B, Welford SM, Cassarino DS, Nickoloff BJ, Giaccia AJ, et al. (2005) The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell 8: 443-454.
39. Rofstad EK, Rasmussen H, Galappathi K, Mathiesen B, Nilsen K, et al. (2002) Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. Cancer Res 62: 1847-1853.
40. Baguley BC, Marshall ES (2004) In vitro modelling of human tumour behaviour in drug discovery programmes. Eur J Cancer 40: 794-801.
41. Marshall ES, Matthews JH, Shaw JH, Nixon J, Tumewu P, et al. (1994) Radiosensitivity of new and established human melanoma cell lines: comparison of [3H]thymidine incorporation and soft agar clonogenic assays. Eur J Cancer 30A: 1370-1376.
42. Rasband WS (1997) Image J. U. S. National Institutes of Health, Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/.
43. Wang TL, Maierhofer C, Speicher MR, Lengauer C, Vogelstein B, et al. (2002) Digital karyotyping. Proc Natl Acad Sci U S A 99: 16156-16161.
44. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, et al. (2006) GenePattern 2. 0. Nat Genet 38: 500-501.
45. Saldanha AJ (2004) Java Treeview-extensible visualization of microarray data. Bioinformatics 20: 3246-3248.
46. Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207-210.
47. Schon M, Wienrich BG, Kneitz S, Sennefelder H, Amschler K, et al. (2008) KINK-1, a novel small-molecule inhibitor of IKKbeta, and the susceptibility of melanoma cells to antitumoral treatment. J Natl Cancer Inst 100: 862-875.
48. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, et al. (2007) Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapopto- tic ligand Apo2L/TRAIL. Nat Med 13: 1070-1077.
49. Chang JT, Nevins JR (2006) GATHER: a systems approach to interpreting genomic signatures. Bioinformatics 22: 2926-2933.
50. He SJ, Stevens G, Braithwaite AW, Eccles MR (2005) Transfection of melanoma cells with antisense PAX3 oligonucleotides additively complements cisplatin-induced cytotoxicity. Mol Cancer Ther 4: 996-1003.